Emergen Research, a globally recognized provider of market research and consulting services, has recently released its latest comprehensive analysis of the global Nutraceuticals CDMO Market. The report provides detailed insights into the market's current landscape, emerging trends, growth opportunities, competitive developments, and future outlook. The research is designed to help businesses, investors, manufacturers, and other stakeholders understand changing market dynamics and identify opportunities across the rapidly evolving nutraceutical contract development and manufacturing industry.
The growing demand for dietary supplements, functional food and beverages, and specialized nutritional products has increased the need for flexible and reliable manufacturing capabilities. Many nutraceutical companies are increasingly outsourcing manufacturing, formulation, development, packaging, and labeling activities to specialized contract development and manufacturing organizations. This allows companies to reduce the capital required for maintaining their own production facilities while concentrating their resources on product development, branding, marketing, and distribution.
The global Nutraceuticals CDMO Market was valued at USD 42.60 Billion in 2025 and is expected to reach USD 46.80 Billion in 2026 and USD 118.40 Billion by 2035, registering a CAGR of 10.9% from 2026 to 2035. North America accounted for the largest market share in 2025, representing 34.2% of global revenue, while Asia Pacific is projected to register the fastest growth during the forecast period.
Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-free-sample/220513
One of the major factors driving the growth of the Nutraceuticals CDMO Market is the increasing outsourcing of manufacturing activities by nutraceutical brand owners. Maintaining an in-house manufacturing facility requires significant investments in production equipment, infrastructure, skilled employees, maintenance, quality systems, and regulatory compliance. By partnering with CDMOs, companies can access established manufacturing capabilities without making comparable investments in their own facilities.
This outsourcing model enables nutraceutical companies to concentrate their capital and resources on formulation, product development, branding, marketing, and customer acquisition. CDMOs can distribute manufacturing infrastructure costs across multiple customers, allowing brand owners to obtain flexible production capacity according to their requirements.
Another important factor supporting market growth is the increasing complexity of nutraceutical dosage forms. Traditional tablets and capsules continue to represent a substantial portion of the market, while demand for softgels, gummies, powders, and liquid formulations is increasing. Each dosage format requires specialized equipment, manufacturing processes, formulation expertise, and quality-control capabilities, encouraging companies to work with specialist manufacturers.
Strategic transactions involving major CDMO businesses are also influencing the industry. On 6 March 2026, Lonza signed a definitive agreement to divest its Capsules & Health Ingredients business, including its Capsugel nutraceutical and health-ingredient manufacturing operations, to Lone Star Funds for an enterprise value of CHF 2.3 Billion, equivalent to approximately USD 3.00 Billion. The transaction highlights the increasing strategic importance of specialized nutraceutical manufacturing assets and the growing involvement of private-equity investors in the segment.
Portfolio consolidation is another factor reshaping the competitive environment. On 18 December 2024, Novo Holdings completed the USD 16.50 Billion all-cash acquisition of Catalent, bringing one of the industry's major end-to-end CDMO networks into the Novo ecosystem. Such transactions are changing ownership structures across the contract manufacturing industry while demand for outsourced nutraceutical production continues to increase.
At the same time, private-equity investment is creating opportunities for dedicated nutraceutical manufacturing platforms. Established manufacturing businesses with specialized facilities, recurring customer relationships, technical capabilities, and established quality systems can provide attractive opportunities for investment and expansion.
The growing complexity of dosage forms is also encouraging brand owners to work with specialist manufacturers. Gummies, for example, require specialized manufacturing processes because active ingredients must be incorporated into a cooked and flavored gelling base. Similar specialized capabilities are required for softgels, liquid formulations, and other advanced nutraceutical formats.
However, the market also faces several challenges. Volatility in the prices of gelatin, plant-based capsule shells, specialty excipients, and other manufacturing inputs can increase production costs for CDMOs and their customers. The escalation of the United States-Iran confrontation in late February 2026 and the uncertainty that continued through the first and second quarters of 2026 added further cost pressure on petrochemical-linked gelatin substitutes and plant-based capsule-shell materials.
Ownership transitions can also create temporary uncertainty for brand customers. Companies may need to reassess manufacturing contracts, pricing arrangements, production capacity, formulation relationships, and continuity of supply following major CDMO transactions. Lonza has also indicated that it expects to recognize an extraordinary non-cash impairment of approximately CHF 1.3 Billion related to the Capsules & Health Ingredients divestiture in its fiscal-year 2025 financial statements.
Odyss by Emergen Research
Emergen Research's Odyss is an AI-powered data intelligence platform designed to provide access to market datasets, research reports, and structured industry intelligence. The platform supports market research, strategic planning, data analysis, and business decision-making across multiple industry verticals.
Odyss provides access to 5,000+ market reports, AI-powered search, exportable datasets, more than 50 industry verticals, and team collaboration capabilities.
Explore Odyss Platform | Talk To An Analyst | View Pricing | Live Platform
The platform can also support businesses requiring customized market intelligence based on specific target segments, regions, competitive requirements, and strategic objectives.
Cost Effective Custom Report
competitive landscape:-
The competitive landscape of the global Nutraceuticals CDMO Market consists of multinational contract development and manufacturing organizations as well as specialized nutraceutical manufacturers. Companies are focusing on expanding manufacturing capacity, strengthening formulation and development capabilities, introducing specialized dosage-form production, and expanding their geographic presence.
Strategic mergers and acquisitions, partnerships, capacity expansion, and management changes are influencing competition across the market. Companies with established manufacturing facilities and specialized technical expertise are increasingly positioned to serve brand owners seeking flexible outsourced production capabilities.
The major competitors in the global Nutraceuticals CDMO Market include:
- Lonza Group AG
- Catalent, Inc.
- Sirio Pharma Co., Ltd.
- Aenova Group
- Best Formulations LLC
- Robinson Pharma, Inc.
- Captek Softgel International, Inc.
- Glanbia plc
- BioHarvest Sciences Inc.
- Thermo Fisher Scientific Inc.
Increasing demand from dietary supplement companies is one of the major factors contributing to the expansion of the market. Dietary supplement brands frequently outsource manufacturing to avoid the high capital requirements associated with establishing their own production infrastructure. The CDMO model allows these companies to access specialized facilities while focusing on product development, branding, and marketing.
The market is also benefiting from the increasing adoption of specialized manufacturing technologies. CDMOs are investing in production capabilities for tablets, capsules, softgels, gummies, powders, and liquids to meet changing customer requirements. Increasing demand for flexible and scalable production is encouraging manufacturers to expand their service portfolios.
Market segmentation:-
Another important aspect of the report is its comprehensive market segmentation. The Nutraceuticals CDMO Market is divided based on service type, dosage form, end user, and key geographical regions. This segmentation provides detailed insights into demand patterns and growth opportunities across different areas of the market.
By service type, the market is segmented into Contract Manufacturing, Contract Formulation & Development, Packaging & Labeling, and Others. Contract Manufacturing accounted for the largest share of the market, representing 61.4% in 2025.
Contract manufacturing remains dominant because brand owners increasingly prefer to outsource physical production rather than invest in dedicated facilities. The Contract Formulation & Development segment is projected to register a CAGR of 13.2% through 2035, supported by increasing demand for external formulation and product-development expertise.
BioHarvest Sciences operates a dedicated CDMO business unit providing development and manufacturing services for plant-based active molecules for pharmaceutical, cosmeceutical, nutraceutical, and nutrition customers. Effective 1 January 2026, the company restructured its internal segment reporting to provide clearer visibility into its CDMO activities separately from its branded consumer products.
Based on dosage form, the market is segmented into Tablets & Capsules, Softgels, Gummies, Powders & Liquids, and Others. Tablets & Capsules held the largest share, accounting for 34.7% of the global market in 2025.
Tablets and capsules continue to be widely used for vitamins, minerals, multivitamins, and other dietary supplements because of their established production processes and high-volume manufacturing capabilities. However, the Gummies segment is projected to register a CAGR of 15.8% through 2035, supported by increasing consumer demand for convenient and appealing supplement formats.
Robinson Pharma expanded its production capabilities in December 2025 by launching a new high-speed liquid production line while also adding tablet, softgel, and capsule manufacturing capacity.
Based on end user, the market is segmented into Dietary Supplement Companies, Functional Food & Beverage Companies, Pharmaceutical Companies, and Others. Dietary Supplement Companies accounted for 52.8% of the market in 2025, making them the largest end-user segment.
Functional Food & Beverage Companies are expected to register a CAGR of 14.1% through 2035, supported by increasing consumer interest in functional nutrition products and the expansion of food and beverage companies into health-oriented product categories.
Aenova Group appointed Alexandre Pasini as Chief Operating Officer in November 2025, strengthening its operational leadership across its CDMO network serving pharmaceutical, biopharmaceutical, and dietary supplement customers.
Custom Requirements can be requested for this Report [Customization Available] @ https://www.emergenresearch.com/request-for-customization/220513
The report is highly beneficial for a wide range of stakeholders, including nutraceutical manufacturers, dietary supplement companies, functional food and beverage companies, pharmaceutical organizations, investors, venture capital firms, consulting companies, research organizations, and other businesses involved in the nutraceutical value chain.
The market's value chain begins with raw-material and packaging suppliers and extends through CDMO manufacturing facilities to brand owners and consumers. Key inputs include gelatin, plant-based capsule shells, active ingredients, excipients, packaging materials, and other manufacturing components.
CDMOs such as Lonza's Capsules & Health Ingredients business, Catalent, Sirio Pharma, and Aenova Group provide manufacturing capabilities across multiple dosage formats. Their revenues are influenced by brand-owner order volumes, contract renewals, manufacturing capacity utilization, product launches, formulation transfers, and production requirements.
The regulatory environment also plays an important role in the market. In the United States, dietary supplement manufacturing operates under the Dietary Supplement Health and Education Act (DSHEA) and current Good Manufacturing Practice requirements under 21 CFR Part 111. These requirements increase the importance of quality systems, documentation, testing, and regulatory compliance within CDMO operations.
The U.S. Food and Drug Administration's Office of Dietary Supplement Programs has also identified areas such as New Dietary Ingredient notifications and mandatory product listing as important regulatory considerations for the dietary supplement industry.
Market Segmentation
- Service Type
- Contract Manufacturing
- Contract Formulation & Development
- Packaging & Labeling
- Others
- Dosage Form
- Tablets & Capsules
- Softgels
- Gummies
- Powders & Liquids
- Others
- End User
- Dietary Supplement Companies
- Functional Food & Beverage Companies
- Pharmaceutical Companies
- Others
- Region
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Benelux
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East and Africa
- Saudi Arabia
- UAE
- South Africa
- Turkey
- Rest of MEA
North America represented the largest regional market in 2025, accounting for 34.2% of global revenue. The region benefits from a strong concentration of dietary supplement companies, established CDMO networks, and a mature regulatory environment.
The United States led the North American market in 2025. The acquisition of Catalent by Novo Holdings further concentrated a major global CDMO network under a single ownership structure. Catalent operates more than 50 sites worldwide and employs more than 18,000 people.
Europe accounted for approximately 27.9% of the global market in 2025. The region has an established base of pharmaceutical and nutraceutical manufacturing capabilities, with Aenova Group and Lonza's former Capsules & Health Ingredients operations representing important participants in the European manufacturing ecosystem.
Lonza reported CHF 6.5 Billion in full-year 2025 CDMO revenue and provided an outlook for 11% to 12% currency-adjusted sales growth in 2026 for its continuing pure-play CDMO operations.
Asia Pacific is projected to be the fastest-growing regional market, with a CAGR of 13.6% through 2035. Increasing manufacturing investment, expanding domestic demand, and growing production requirements from international nutraceutical brands are supporting the region's growth.
Sirio Pharma is among the companies expanding its manufacturing footprint in Asia Pacific to address growing demand from domestic and international customers.
Latin America is projected to register a CAGR of 8.9% through 2035, supported by increasing outsourcing activity and expanding manufacturing capabilities in countries such as Brazil and Mexico.
The Middle East and Africa market is projected to grow at a CAGR of 7.8% through 2035, with Saudi Arabia and the UAE representing important markets contributing to regional development.
The Nutraceuticals CDMO Market is also supported by continued investment in specialized manufacturing capabilities. As companies introduce more complex products and expand their product portfolios, the ability to provide integrated formulation, manufacturing, packaging, quality, and regulatory services is becoming increasingly important.
The market is expected to continue benefiting from the shift toward outsourced production. Brand owners are increasingly seeking manufacturing partners that can provide flexible capacity, specialized dosage-form expertise, and support throughout the product-development lifecycle.
Recent industry developments are further influencing the competitive landscape. On 6 March 2026, Lonza announced its agreement to divest its Capsules & Health Ingredients business to Lone Star Funds for an enterprise value of CHF 2.3 Billion. The transaction includes Capsugel nutraceutical and health-ingredient manufacturing operations and is expected to close in the second half of 2026, subject to applicable conditions.
On 18 December 2024, Novo Holdings completed its USD 16.50 Billion acquisition of Catalent. Novo Nordisk separately agreed to acquire three Catalent fill-finish sites in Italy, Belgium, and Indiana for USD 11 Billion, while the remainder of Catalent continued as a standalone CDMO business under Novo Holdings.
On 1 January 2026, BioHarvest Sciences restructured its internal reporting structure to separately report its CDMO business from its branded consumer products activities.
One of the major strengths of the Nutraceuticals CDMO Market report is its comprehensive analysis of market trends, growth drivers, restraints, segmentation, regional developments, competitive activity, and future opportunities. The research provides businesses with information that can support strategic planning, market expansion, investment decisions, and competitive analysis.
The report also provides detailed market forecasts and analysis across different service types, dosage forms, end-user categories, and geographic regions. This enables stakeholders to evaluate changing demand patterns and identify areas of potential growth.
Browse Full Report Description + Research Methodology + Table of Content + Infographics @ https://www.emergenresearch.com/industry-report/nutraceuticals-cdmo-market
The global Nutraceuticals CDMO Market is expected to grow from USD 42.60 Billion in 2025 to USD 118.40 Billion by 2035, registering a CAGR of 10.9% from 2026 to 2035. Increasing manufacturing outsourcing, growing dosage-form complexity, private-equity investment, portfolio restructuring, and rising demand for specialized nutraceutical products are expected to remain important factors influencing the market during the forecast period.
About Emergen Research
Emergen Research is a leading market research and consulting company that specializes in providing syndicated research reports, customized research solutions, and consulting services. The company focuses on helping clients understand changing market dynamics, identify growth opportunities, and make informed business decisions. With research coverage across multiple industries and regions, Emergen Research provides market intelligence covering industry trends, market size, competitive landscapes, regional analysis, growth opportunities, and strategic developments.
Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research | Web:
Direct Line: +1 (604) 757-9756
E-mail: [email protected]
